Patents by Inventor Edward Flanagan

Edward Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230009153
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: August 4, 2021
    Publication date: January 12, 2023
    Applicant: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • Patent number: 11360788
    Abstract: A configuration control transfer (“CCT”) system controls the transferring of control of configuration information of a device from a current configuration source to a target configuration source. A CCT server of the CCT system may send a request for the configuration information of the device where the configuration information of the device currently under control of the at least one first configuration source. The CCT server may also receive the requested configuration information, determine whether the second configuration source is able to support the configuration information of the first configuration source, and based at least on a determination that the second configuration source is able to support the configuration information, request that the device transfer control of the configuration information from the first configuration source to the second configuration source to unenroll the device with the first configuration source and enroll the device with the second configuration source.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: June 14, 2022
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Tanvir Ahmed, Peter J. Kaufman, Shayak Lahiri, John Chadwell Spaith, Janani Vasudevan, Dennis Edward Flanagan
  • Patent number: 11111242
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylam ides and analogues thereof, having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: September 7, 2021
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • Publication number: 20200257542
    Abstract: A configuration control transfer (“CCT”) system controls the transferring of control of configuration information of a device from a current configuration source to a target configuration source. A CCT server of the CCT system may send a request for the configuration information of the device where the configuration information of the device currently under control of the at least one first configuration source. The CCT server may also receive the requested configuration information, determine whether the second configuration source is able to support the configuration information of the first configuration source, and based at least on a determination that the second configuration source is able to support the configuration information, request that the device transfer control of the configuration information from the first configuration source to the second configuration source to unenroll the device with the first configuration source and enroll the device with the second configuration source.
    Type: Application
    Filed: March 31, 2020
    Publication date: August 13, 2020
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Tanvir Ahmed, Peter J. Kaufman, Shayak Lahiri, John Chadwell Spaith, Janani Vasudevan, Dennis Edward Flanagan
  • Patent number: 10732150
    Abstract: A sensor device includes: a probe body having a first end and a second end, the probe body defining a probe cavity within the probe body; a sensor located at the first end of the probe body, the sensor having a sensor surface in sensory communication with the probe cavity defined within the probe body; a permanent magnet located adjacent the second end of the probe body and at least partially circumscribing the probe cavity defined within the probe body; an isolating boundary portion located between the permanent magnet and a surface of the object of interest and having a passage formed therethrough, the passage in communication with the probe cavity defined within the probe body.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 4, 2020
    Inventor: Edward Flanagan
  • Patent number: 10703756
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: July 7, 2020
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo, Sidney Xi Liang
  • Patent number: 10628174
    Abstract: A configuration control transfer (“CCT”) system controls the transferring of control of configuration information of a device from a current configuration source to a target configuration source. A CCT server of the CCT system may send to the device a message requesting the configuration information of the device. In response, a CCT client of the CCT system collects the configuration information of the device and sends the collected configuration information to the CCT server. If the second configuration source can support the configuration information of the current configuration source, the CCT server requests that the device transfer control of the configuration information from the current configuration source to the target configuration source. The CCT client then transfers control of the configuration information to the target configuration source as the new current configuration source and un-enrolls the device from the former current configuration source.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Tanvir Ahmed, Peter J. Kaufman, Shayak Lahiri, John Chadwell Spaith, Janani Vasudevan, Dennis Edward Flanagan
  • Publication number: 20190072525
    Abstract: A sensor device includes: a probe body having a first end and a second end, the probe body defining a probe cavity within the probe body; a sensor located at the first end of the probe body, the sensor having a sensor surface in sensory communication with the probe cavity defined within the probe body; a permanent magnet located adjacent the second end of the probe body and at least partially circumscribing the probe cavity defined within the probe body; an isolating boundary portion located between the permanent magnet and a surface of the object of interest and having a passage formed therethrough, the passage in communication with the probe cavity defined within the probe body.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 7, 2019
    Inventor: Edward Flanagan
  • Patent number: 10216297
    Abstract: A flexible, scalable hardware input device for interacting with a variety of devices ranging from a phone, to a media playback device to a steering wheel or a tablet PC is provided. The input device includes a set of mechanical input controls, each mapping to one or more independent functions and a set of touch sensitive input control areas (e.g., capacitive), where each touch sensitive input control area receives touch input independently. In addition, one or more of the touch sensitive input control areas interchangeably overlay one or more of the mechanical input controls, whereby interaction with the touch sensitive input control areas is processed together to determine a corresponding function for controlling the application, service or computing device.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: February 26, 2019
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Brett Allen Bentsen, Dennis Edward Flanagan, Gregory Sean Cox, Thamer A. Abanami
  • Publication number: 20190002466
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: April 19, 2016
    Publication date: January 3, 2019
    Applicant: Pfizer Inc.
    Inventors: Atli THORARENSEN, Matthew Frank BROWN, Agustin CASIMIRO-GARCIA, Ye CHE, Mark Edward FLANAGAN, Adam Matthew GILBERT, Matthew Merrill HAYWARD, Jean-Baptiste TELLIEZ, Rayomand Jal UNWALLA, John I. TRUJILLO, Sidney Xi LIANG
  • Publication number: 20170247372
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: March 1, 2017
    Publication date: August 31, 2017
    Applicant: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • Publication number: 20170235583
    Abstract: A configuration control transfer (“CCT”) system controls the transferring of control of configuration information of a device from a current configuration source to a target configuration source. A CCT server of the CCT system may send to the device a message requesting the configuration information of the device. In response, a CCT client of the CCT system collects the configuration information of the device and sends the collected configuration information to the CCT server. If the second configuration source can support the configuration information of the current configuration source, the CCT server requests that the device transfer control of the configuration information from the current configuration source to the target configuration source. The CCT client then transfers control of the configuration information to the target configuration source as the new current configuration source and un-enrolls the device from the former current configuration source.
    Type: Application
    Filed: February 17, 2016
    Publication date: August 17, 2017
    Inventors: Tanvir Ahmed, Peter J. Kaufman, Shayak Lahiri, John Chadwell Spaith, Janani Vasudevan, Dennis Edward Flanagan
  • Patent number: 9617258
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • Patent number: 9549929
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: January 24, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Patent number: 9545405
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 17, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Publication number: 20150246048
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Publication number: 20150225408
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Application
    Filed: April 21, 2015
    Publication date: August 13, 2015
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Publication number: 20150158864
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 11, 2015
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla
  • Patent number: 9035074
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: May 19, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Publication number: 20150009148
    Abstract: A flexible, scalable hardware input device for interacting with a variety of devices ranging from a phone, to a media playback device to a steering wheel or a tablet PC is provided. The input device includes a set of mechanical input controls, each mapping to one or more independent functions and a set of touch sensitive input control areas (e.g., capacitive), where each touch sensitive input control area receives touch input independently. In addition, one or more of the touch sensitive input control areas interchangeably overlay one or more of the mechanical input controls, whereby interaction with the touch sensitive input control areas is processed together to determine a corresponding function for controlling the application, service or computing device.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Inventors: Brett Allen Bentsen, Dennis Edward Flanagan, Gregory Sean Cox, Thamer A. Abanami